New medical device extremely effective at preventing HIV in women

Study: New medical device extremely effective at preventing HIV in women

It's often said that the HIV/AIDS epidemic has a woman's face. The proportion of women infected with HIV has been on the rise for a decade; in sub-Saharan Africa, women constitute 60 percent of people living with disease. While preventative drugs exist, they have often proven ineffective, especially in light of financial and cultural barriers in developing nations.

A new intravaginal ring filled with an anti-retroviral drug could help. Developed with support from the National Institute of Allergy and Infectious Diseases by Northwestern University visiting associate professor Patrick Kiser, the ring is easy to use, long lasting, and recently has demonstrated a 100 percent success rate protecting primates from the simian immunodeficiency virus (SHIV). The device will soon undergo its first test in humans.

"After 10 years of work, we have created an intravaginal ring that can prevent against multiple HIV exposures over an extended period of time, with consistent prevention levels throughout the ," said Kiser, an expert in intravaginal who joined Northwestern from the University of Utah, where the research was conducted.

Kiser is a new faculty member in Northwestern's McCormick School of Engineering's Department of Biomedical Engineering and visiting associate professor of in the Feinberg School of Medicine.

The research was published September 16 in the Proceedings of the National Academy of Sciences (PNAS).

Previous studies have demonstrated that antiviral drugs can prevent HIV infection, but existing methods for delivering the drug fall short. Pills must be taken daily and require high doses; vaginal gels that must be applied prior to each sex act are inconvenient, yielding poor usage rates.

The new ring is easily inserted and stays in place for 30 days. And because it is delivered at the site of transmission, the ring—known as a TDF-IVR (tenofovir disoproxil fumarate intravaginal ring)—utilizes a smaller dose than pills.

The device contains powdered , an anti-retroviral drug that is taken orally by 3.5 million HIV-infected people worldwide, but that has not previously been studied topically. But the ring's strength stems from its unique polymer construction: its elastomer swells in the presence of fluid, delivering up to 1,000 times more of the drug than current intravaginal ring technology, such as NuvaRing, which are made of silicon and have release rates that decline over time.

The upcoming clinical trial, to be conducted in November at Albert Einstein College of Medicine in New York, will evaluate the ring in 60 women over 14 days. The trial will assess the ring's safety and measure how much of the drug is released and the properties of the ring after use.

Other drugs could potentially be integrated into the ring, such as contraceptives or to prevent other sexually transmitted infections—a feature that could increase user rates, Kiser said.

"The flexibility to engineer this system to deliver multiple drugs and change release rates is extraordinary and could have a significant impact on women's health," he said.

More information: The paper is titled "Intravaginal Ring Eluting Tenofovir Disoproxil Fumarate Completely Protects Macaques from Multiple Vaginal Simian-HIV Challenges."

Related Stories

Novel intravaginal ring shows promise in HIV prevention

Oct 16, 2012

A new 90-day intravaginal ring has been developed—that for the first time—enables the long-lasting vaginal delivery of tenofovir (TFV), the only topical prophylactic shown to be effective at reducing the sexual transmission ...

HIV and AIDS prevention—Progress and the challenges ahead

Nov 05, 2012

At least 2 million people worldwide will be infected with HIV this year, driving the need for better HIV prevention strategies to slow the global pandemic. A better understanding of how to prevent HIV transmission using antiviral ...

Einstein to develop anti-HIV drug delivery system

Oct 02, 2009

The National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a four-year, $7.2 million grant to develop a microbicide-releasing vaginal ring to prevent HIV transmission.

Anti-HIV vaginal gel promising protection in Africa, SE asia

Apr 20, 2011

A new vaginal microbicide gel and drug formulation looks promising for empowering women in developing countries to protect themselves from HIV during intercourse, without having to inform their partners, according to research ...

Recommended for you

HIV lessons from the Mississippi Baby

Aug 29, 2014

(Medical Xpress)—The news in July that HIV had returned in a Mississippi toddler after a two-year treatment-free remission dashed the hopes of clinicians, HIV researchers and the public at large tantalized ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Shootist
1 / 5 (9) Sep 27, 2013
It has never been said that HIV has a women's face. WTF are you people thinking?
Karlito
not rated yet Sep 27, 2013
-
Dug
5 / 5 (1) Sep 28, 2013
Shootist - You need to read up more on the subject. The rate of most sexually transmitted diseases is higher in women simply because their anatomy is conducive to the incubation of them. Men (hetro or homo-sexual preferences) and especially women who have STDs that provide skin breakage also provide better opportunistic entry points for the HIV virus - and probably other STDs. Consequently there is a high correlation between non-HIV STD's and HIV infection rates. In Africa, Asia and Russia and unlike the US, most HIV is transmitted by prostitutes with STD's and their higher probability of having HIV. When HIV was first discovered it was also discovered that spermicides (detergent based - especially with condoms) were effective in destroying the outer covering of the HIV virus and about 95+% effective. This knowledge did not significantly alter sexual habits - or HIV transmission globally. This rings chance may be equally ineffective given ignorance, cost and lack of effective use.